Quarterly ResultMay 14, 2026, 04:09 PM
Sangamo Therapeutics Reports Q1 Net Loss $31M; Going Concern Doubt
AI Summary
Sangamo Therapeutics reported a net loss of $30.995 million for the first quarter of 2026, with revenues significantly decreasing to $1.442 million from $6.437 million in the prior year. The company disclosed substantial doubt about its ability to continue as a going concern due to a history of significant losses, negative cash flows, limited liquidity, and dependence on additional financing. Management is pursuing various strategies, including equity sales and collaborations, to secure necessary capital.
Key Highlights
- Substantial doubt exists about Sangamo's ability to continue as a going concern.
- Net loss for Q1 2026 was $30.995 million, compared to $30.597 million in Q1 2025.
- Revenues for Q1 2026 decreased to $1.442 million from $6.437 million in Q1 2025.
- Cash and cash equivalents stood at $27.586 million as of March 31, 2026.
- Total stockholders' deficit was $(18.955) million as of March 31, 2026.
- Basic and diluted net loss per share was $(0.08) for Q1 2026.
- Total operating expenses for Q1 2026 were $33.388 million.
Price Impact
More from SGMO